Veradermics, Incorporated
Price
Key statistics
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
Veradermics, Incorporated is a late clinical-stage biopharmaceutical company focused on developing dermatology and aesthetic treatments. Its current pipeline centers on therapies for pattern hair loss, including VDPHL01, an oral, non-hormonal, extended-release minoxidil formulation designed for men and women. The company is also developing additional product candidates and delivery technologies for common skin and hair-related conditions such as alopecia areata, common warts, molluscum contagiosum, and atopic dermatitis. Veradermics serves healthcare providers, dermatology clinicians, and medical researchers involved in treating adult and pediatric patients. Headquartered in New Haven, Connecticut, and incorporated in 2019, Veradermics operates as a focused biotech company addressing prevalent dermatologic conditions through targeted therapeutic development.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Reid Waldman M.D.
- Employees
- 37
- Headquarters
- New Haven, CT, United States
- Website
- www.veradermics.com